Pseudovirus News and Research

RSS

Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

Researchers explored the virological profiles of novel SARS-CoV-2 Omicron variants.

30 May 2022

Continuous evolution of SARS-CoV-2 Omicron variant yielding immune evasive subvariants

Researchers reported findings of a systematic antigenic analysis of the circulating SARS-CoV-2 Omicron subvariants such as BA.2.12.1, BA.4, and BA.5.

30 May 2022

Direct comparison of immune memory responses to four COVID-19 vaccines

Researchers evaluated host immune responses to four COVID-19 vaccines representing three different vaccine technology platforms, focusing on immune memory responses.

30 May 2022

Pediatric patients with prior COVID-19 or MIS-C are not protected against Omicron

Research drawing on the national Overcoming COVID-19 study, led by Boston Children's Hospital, and the hospital's own Taking On COVID-19 Together Group provides evidence that children who previously had COVID-19 (or the inflammatory condition MIS-C) are not protected against the newer Omicron variant.

27 May 2022

Hamster contact exposure challenge model assesses protection conferred by SARS-CoV-2 vaccination or prior infection against reinfection

Researchers assessed the neutralization efficacy of a saRNA vaccine targeting SARS-CoV-2 S protein against reinfection among hamsters with prior vaccination or infection.

24 May 2022

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Resarchers discuss the ability of shark-derived antibodies to protect against multiple variants of SARS-CoV-2.

23 May 2022

SARS-CoV-2 Omicron subvariants are increasingly escaping immunity

In a recent study posted to the medRxiv* preprint server, researchers evaluated the neutralization evasion of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages.

22 May 2022

Neutralizing antibody responses induced by COVID-19 vaccines against SARS-CoV-2 variants

In a new study, researchers evaluated the ability of vaccine-induced antibodies to recognize and neutralize various SARS-CoV-2 variants of concern in SARS-CoV-2-naive health care workers in the Netherlands.

19 May 2022

Recombinant protein vaccine stands up to SARS-CoV-2 variants

A study by researchers in Texas describes a mouse model in which a subunit vaccine with alum-CpG adjuvant was tested for its ability to induce a broadly neutralizing antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 May 2022

Study explores lipid nanoparticles against SARS-CoV-2

Researchers assessed the efficiency of lipid nanoparticles against SARS-CoV-2.

18 May 2022

Compound found in Datura shows promise as antiviral agent against SARS-CoV-2

Researchers from Naval Medical University have been investigating anisodamine, used in traditional Chinese medicine, to inhibit SARS-CoV-2 infection in cellular models. The study is published in the journal Biochemical and Biophysical Research Communications.

17 May 2022

3rd dose of COVID mRNA vaccine expands memory and capacity of immune system to combat Omicron

Researchers from the United States have now found that the immune recall induced by a two-dose primary series of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination after an initial natural infection highly improves the longevity of the antibodies as well as induces an enhanced breadth of protection across the SARS-CoV-2 variants.

17 May 2022

Triple vaccination found to confer immune protection against SARS-CoV-2 Omicron BA.2 sublineage

Researchers assessed the immune responses induced by two doses or three doses of the BNT162b2 (BNT) or the CoronaVac (CorV) vaccine against SARS-CoV-2 Omicron BA.2 sublineage among public servants working for the government of Hong Kong.

16 May 2022

Delta- and Omicron BA.1-variant specificity of B cell repertoires established by an initial Wuhan strain infection

Researchers performed an unbiased evaluation of the early memory B cell repertoire specific for the Omicron and Delta variants of SARS-CoV-2.

12 May 2022

Decoy ACE2 nanoparticles block the entry of SARS-CoV-2 into cells

In a recent study posted to the bioRxiv* preprint server, researchers reported that nanoparticles could prevent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cell entry.

10 May 2022

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

A study recently published in the journal Cell Host & Microbe has described that all three sublineages of the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar host cell entry efficiency and are neutralized equally by antibodies generated in response to coronavirus disease 2019 (COVID-19) booster vaccination

10 May 2022

Infection with SARS-CoV-2 results in antibodies against common colds

A study published in the journal Science Advances uses electron microscopy-based polyclonal epitope mapping (EMPEM) methodology to elucidate the spike epitopes of β-HCoV targeted by preexisting serum antibodies and compares them to the epitopes targeted by antibodies elicited by SARS-CoV-2 infection using electron microscopy-based polyclonal epitope mapping (EMPEM) methodology.

8 May 2022

Efficacy and safety of a 3rd dose of mRNA-1273 SARS-CoV-2 vaccine

In a recent study posted to the Research Square* preprint server, researchers tested the safety and immunogenicity of a third dose of coronavirus disease 2019 (COVID-19) prototype messenger ribonucleic acid (mRNA)-1273 versus a variant vaccine and a bivalent vaccine formulation.

5 May 2022

SARS-CoV-2 Omicron BA.2.12.1, BA.4 and BA.5 subvariants are superior to their predecessors

A recent study posted to the bioRxiv* preprint server demonstrated that the latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages evade immunity imparted by the prior subvariants.

5 May 2022

Phase 2 clinical trial of COVID-19 convalescent plasma with high antibody titers

Researchers determined the threshold neutralizing antibody titer for effective COVID-19 convalescent plasma therapy.

4 May 2022

Pseudovirus News and Research

Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

Continuous evolution of SARS-CoV-2 Omicron variant yielding immune evasive subvariants

Direct comparison of immune memory responses to four COVID-19 vaccines

Pediatric patients with prior COVID-19 or MIS-C are not protected against Omicron

Hamster contact exposure challenge model assesses protection conferred by SARS-CoV-2 vaccination or prior infection against reinfection

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

SARS-CoV-2 Omicron subvariants are increasingly escaping immunity

Neutralizing antibody responses induced by COVID-19 vaccines against SARS-CoV-2 variants

Recombinant protein vaccine stands up to SARS-CoV-2 variants

Study explores lipid nanoparticles against SARS-CoV-2

Compound found in Datura shows promise as antiviral agent against SARS-CoV-2

3rd dose of COVID mRNA vaccine expands memory and capacity of immune system to combat Omicron

Triple vaccination found to confer immune protection against SARS-CoV-2 Omicron BA.2 sublineage

Delta- and Omicron BA.1-variant specificity of B cell repertoires established by an initial Wuhan strain infection

Decoy ACE2 nanoparticles block the entry of SARS-CoV-2 into cells

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

Infection with SARS-CoV-2 results in antibodies against common colds

Efficacy and safety of a 3rd dose of mRNA-1273 SARS-CoV-2 vaccine

SARS-CoV-2 Omicron BA.2.12.1, BA.4 and BA.5 subvariants are superior to their predecessors

Phase 2 clinical trial of COVID-19 convalescent plasma with high antibody titers

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News